"""
Question: 1101

Evidence: We herein report the first efficacy and safety data of a ran- domized, clinical switch trial of once-daily DTG in combina- tion with boosted DRV in pretreated patients with HIV-1 who have been suppressed for at least 6 months.

Rationale: The paper explicitly states that it reports "the first efficacy and safety data" from this randomized clinical switch trial, indicating that this is previously unpublished data from their study.

Answer: Yes
"""

"""
Question: 1102

Evidence: Numbers of historic genotypic resistance testing did not differ between the 2 groups and were available in 84 (64.1%) subjects in the 2DR group and 83 (62.9%) in the 3DR group; 20.9% in the 2DR group and 11.0% in the 3DR group had a history of ≥2 NRTI and ≥2 PI changes, respectively. Relevant rates of NRTI, non-NRTI, and major PI resistance--associated mutations (RAMs) were observed in 9.9% vs 9.1%, 15.3% vs 13.6%, and 3.8% vs 3.0% of the 2DR and 3DR groups, respectively.

Rationale: The paper mentions "historic genotypic resistance testing" and reports on "resistance-associated mutations (RAMs)" found in participants, indicating that HIV sequences were analyzed as part of the study.

Answer: Yes
"""

"""
Question: 1103

Evidence: No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: The paper does not mention any in vitro passage experiments. It focuses on clinical trial outcomes, safety, and efficacy in human subjects, with no reference to laboratory-based passage experiments.

Answer: No
"""

"""
Question: 1104

Evidence: No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: The paper does not report any in vitro antiretroviral susceptibility data. It focuses on clinical outcomes, resistance mutations from historical testing, but no laboratory susceptibility testing results.

Answer: No
"""

"""
Question: 2101

Evidence: No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: The paper does not mention any GenBank accession numbers for sequenced HIV isolates. It reports on resistance mutations from historical testing but does not indicate that sequences were deposited in GenBank.

Answer: No
"""

"""
Question: 2102

Evidence: No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: The paper does not report any GenBank accession numbers for sequenced HIV isolates, either for laboratory isolates or clinical isolates.

Answer: No
"""

"""
Question: 2103

Evidence: No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: The paper does not mention any GenBank accession numbers throughout the text.

Answer: NA
"""

"""
Question: 2202

Evidence: Relevant rates of NRTI, non-NRTI, and major PI resistance--associated mutations (RAMs) were observed in 9.9% vs 9.1%, 15.3% vs 13.6%, and 3.8% vs 3.0% of the 2DR and 3DR groups, respectively.

Rationale: The paper reports aggregate prevalence rates of resistance-associated mutations by drug class but does not provide lists of mutations for individual sequenced HIV isolates.

Answer: No
"""

"""
Question: 2301

Evidence: Investigators enrolled subjects aged ≥18 years with documented HIV-1 infection.

Rationale: The paper specifically states that all participants had "HIV-1 infection," indicating that HIV-1 was the only species studied.

Answer: HIV-1
"""

"""
Question: 2302

Evidence: No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: The paper does not report any information about HIV subtypes of the sequenced viruses.

Answer: NA
"""

"""
Question: 2303

Evidence: Relevant rates of NRTI, non-NRTI, and major PI resistance--associated mutations (RAMs) were observed in 9.9% vs 9.1%, 15.3% vs 13.6%, and 3.8% vs 3.0% of the 2DR and 3DR groups, respectively.

Rationale: The paper mentions resistance-associated mutations for NRTI, non-NRTI, and PI drug classes, which would typically involve sequencing of the pol gene, but does not explicitly state which genes were sequenced.

Answer: NA
"""

"""
Question: 2304

Evidence: Relevant rates of NRTI, non-NRTI, and major PI resistance--associated mutations (RAMs) were observed in 9.9% vs 9.1%, 15.3% vs 13.6%, and 3.8% vs 3.0% of the 2DR and 3DR groups, respectively.

Rationale: The paper reports resistance-associated mutations for NRTI, non-NRTI, and PI drug classes, which are typically located in the pol gene, suggesting that HIV pol sequences were analyzed.

Answer: Yes
"""

"""
Question: 2401

Evidence: The DUALIS study is a randomized, open-label, multicenter, noninferiority, phase 3 trial conducted at 27 active study centers in Germany.

Rationale: The paper states that the study was conducted at centers in Germany, indicating that all sequences came from Germany.

Answer: Germany
"""

"""
Question: 2402

Evidence: Between July 31, 2015, and June 6, 2017, PWH (subjects) at the dedicated centers were screened (n = 269) for eligibility.

Rationale: The paper provides the screening period (July 2015 to June 2017) during which participants were enrolled, indicating when samples were likely obtained.

Answer: 2015-2017
"""

"""
Question: 2502

Evidence: Resistance testing was performed at the discretion of the investigator according to the local guidelines and at any time of confirmed virologic failure.

Rationale: The paper does not specify which sequencing method was used for resistance testing, only that it was performed according to local guidelines.

Answer: NA
"""

"""
Question: 2503

Evidence: Resistance testing was performed at the discretion of the investigator according to the local guidelines and at any time of confirmed virologic failure.

Rationale: The paper does not specify whether NGS technology was used for sequencing, only mentioning that resistance testing was performed according to local guidelines.

Answer: NA
"""

"""
Question: 2504

Evidence: No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: The paper does not mention any cloning procedures being performed prior to sequencing.

Answer: No
"""

"""
Question: 2505

Evidence: No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: The paper does not mention single genome sequencing being performed.

Answer: No
"""

"""
Question: 2506

Evidence: No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: The paper does not mention molecular cloning being performed.

Answer: No
"""

"""
Question: 2601

Evidence: Resistance testing was performed at the discretion of the investigator according to the local guidelines and at any time of confirmed virologic failure, defined as HIV RNA >200 copies/mL in 2 consecutive measures.

Rationale: The paper mentions resistance testing being performed at virologic failure, which would typically involve plasma virus sequencing when HIV RNA is detectable.

Answer: Yes
"""

"""
Question: 2602

Evidence: No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: The paper does not mention PBMC HIV sequencing or proviral DNA sequencing.

Answer: No
"""

"""
Question: 2603

Evidence: Kaplan-Meier estimates of confirmed HIV RNA ≥50 copies/mL at W48 were 1.6% (n = 2) in the 2DR and 3.1% (n = 4) in the 3DR group.

Rationale: The paper does not provide specific numbers of samples that underwent plasma virus sequencing, only reporting numbers of participants with virologic failure.

Answer: NA
"""

"""
Question: 2604

Evidence: No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: The paper does not mention PBMC virus sequencing being performed.

Answer: NA
"""

"""
Question: 2605

Evidence: Kaplan-Meier estimates of confirmed HIV RNA ≥50 copies/mL at W48 were 1.6% (n = 2) in the 2DR and 3.1% (n = 4) in the 3DR group.

Rationale: The paper reports that a small number of participants had confirmed virologic failure with HIV RNA ≥50 copies/mL, indicating sequences were obtained from individuals with active HIV replication in these cases.

Answer: Yes
"""

"""
Question: 2606

Evidence: No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: The paper does not mention sequences being obtained from the proviral DNA reservoir.

Answer: No
"""

"""
Question: 2701

Evidence: Investigators enrolled subjects aged ≥18 years with documented HIV-1 infection.

Rationale: The paper explicitly states that participants were aged ≥18 years, indicating no infants or children were included in the study.

Answer: No
"""

"""
Question: 2702

Evidence: The DUALIS study is a randomized, open-label, multicenter, noninferiority, phase 3 trial.

Rationale: The paper describes the DUALIS study as a randomized clinical trial, indicating that all individuals in the paper were in a clinical trial.

Answer: Yes
"""

"""
Question: 2703

Evidence: The DUALIS study is a randomized, open-label, multicenter, noninferiority, phase 3 trial.

Rationale: The entire study population consisted of participants in the DUALIS clinical trial, so all individuals in the paper were in this clinical trial.

Answer: Yes
"""

"""
Question: 3101

Evidence: Numbers of historic genotypic resistance testing did not differ between the 2 groups and were available in 84 (64.1%) subjects in the 2DR group and 83 (62.9%) in the 3DR group.

Rationale: The paper reports that historic genotypic resistance testing was available for 84 subjects in the 2DR group and 83 subjects in the 3DR group, totaling 167 individuals who had samples obtained for HIV sequencing.

Answer: 167
"""

"""
Question: 3102

Evidence: Numbers of historic genotypic resistance testing did not differ between the 2 groups and were available in 84 (64.1%) subjects in the 2DR group and 83 (62.9%) in the 3DR group.

Rationale: The paper indicates that not all participants had historic genotypic resistance testing available (only 64.1% in 2DR group and 62.9% in 3DR group), so not all individuals underwent HIV sequencing.

Answer: No
"""

"""
Question: 4101

Evidence: PWH with HIV RNA <50 copies/ mL taking 2NRTI + bDRV (3DR) for ≥24 weeks (1 accepted blip <200 copies/mL) were randomized to either switch to DTG 50 mg + DRV 800 mg (boosted with 100 mg of ritonavir) or continue taking 3DR.

Rationale: The paper describes that all participants were already on antiretroviral therapy (2NRTI + bDRV) for at least 24 weeks before enrollment, indicating they were all ART-experienced, not ART-naive.

Answer: No
"""

"""
Question: 4102

Evidence: PWH with HIV RNA <50 copies/ mL taking 2NRTI + bDRV (3DR) for ≥24 weeks (1 accepted blip <200 copies/mL) were randomized to either switch to DTG 50 mg + DRV 800 mg (boosted with 100 mg of ritonavir) or continue taking 3DR.

Rationale: The paper explicitly states that all participants were taking antiretroviral therapy (2NRTI + bDRV) for at least 24 weeks before enrollment, indicating they were all ART-experienced.

Answer: Yes
"""

"""
Question: 4103

Evidence: PWH with HIV RNA <50 copies/ mL taking 2NRTI + bDRV (3DR) for ≥24 weeks (1 accepted blip <200 copies/mL) were randomized to either switch to DTG 50 mg + DRV 800 mg (boosted with 100 mg of ritonavir) or continue taking 3DR.

Rationale: The paper indicates that all participants were ART-experienced, with no mention of ART-naive individuals.

Answer: No
"""

"""
Question: 4104

Evidence: PWH with HIV RNA <50 copies/ mL taking 2NRTI + bDRV (3DR) for ≥24 weeks (1 accepted blip <200 copies/mL) were randomized to either switch to DTG 50 mg + DRV 800 mg (boosted with 100 mg of ritonavir) or continue taking 3DR.

Rationale: The paper states that all participants were on ART for at least 24 weeks before enrollment, so there were no samples from ART-naive individuals.

Answer: 0
"""

"""
Question: 4105

Evidence: Time on previous ART, median (IQR), mo  </td><td>   50 (27–69)  </td><td>   38 (17–65)

Rationale: The paper provides some ART history information (time on previous ART, NRTI backbone combinations) but does not indicate that complete ART history information was provided for all individuals.

Answer: No
"""

"""
Question: 4201

Evidence: PWH with HIV RNA <50 copies/ mL taking 2NRTI + bDRV (3DR) for ≥24 weeks (1 accepted blip <200 copies/mL) were randomized to either switch to DTG 50 mg + DRV 800 mg (boosted with 100 mg of ritonavir) or continue taking 3DR.

Rationale: The paper focuses on virologically suppressed individuals switching therapies, not on transmitted HIV drug resistance in treatment-naive populations.

Answer: No
"""

"""
Question: 4202

Evidence: PWH with HIV RNA <50 copies/ mL taking 2NRTI + bDRV (3DR) for ≥24 weeks (1 accepted blip <200 copies/mL) were randomized to either switch to DTG 50 mg + DRV 800 mg (boosted with 100 mg of ritonavir) or continue taking 3DR.

Rationale: The paper focuses on virologically suppressed individuals already on treatment, not on pretreatment HIV drug resistance.

Answer: No
"""

"""
Question: 4301

Evidence: Subjects were randomized 1:1 using a sequence generated with nQuery Advisor 7.0 (Statsols, Cork, Ireland) to either receive oral DTG 50 mg once daily in combination with DRV 800 mg once daily and ritonavir 100 mg daily (2DR) or continue their regimen consisting of 2 NRTIs in combination with ritonavir-boosted DRV (3DR) once a day for a total study duration of 48 weeks.

Rationale: The paper describes that participants received NRTIs, protease inhibitors (darunavir/ritonavir), and integrase inhibitors (dolutegravir).

Answer: NRTIs, protease inhibitors, integrase inhibitors
"""

"""
Question: 4302

Evidence: Subjects were randomized 1:1 using a sequence generated with nQuery Advisor 7.0 (Statsols, Cork, Ireland) to either receive oral DTG 50 mg once daily in combination with DRV 800 mg once daily and ritonavir 100 mg daily (2DR) or continue their regimen consisting of 2 NRTIs in combination with ritonavir-boosted DRV (3DR) once a day for a total study duration of 48 weeks.

Rationale: The paper explicitly mentions that the intervention group received dolutegravir (DTG), which is an integrase inhibitor.

Answer: Yes
"""

"""
Question: 4303

Evidence: Subjects were randomized 1:1 using a sequence generated with nQuery Advisor 7.0 (Statsols, Cork, Ireland) to either receive oral DTG 50 mg once daily in combination with DRV 800 mg once daily and ritonavir 100 mg daily (2DR) or continue their regimen consisting of 2 NRTIs in combination with ritonavir-boosted DRV (3DR) once a day for a total study duration of 48 weeks.

Rationale: The paper explicitly states that all participants received darunavir (DRV) boosted with ritonavir, which is a protease inhibitor.

Answer: Yes
"""

"""
Question: 4304

Evidence: Subjects were randomized 1:1 using a sequence generated with nQuery Advisor 7.0 (Statsols, Cork, Ireland) to either receive oral DTG 50 mg once daily in combination with DRV 800 mg once daily and ritonavir 100 mg daily (2DR) or continue their regimen consisting of 2 NRTIs in combination with ritonavir-boosted DRV (3DR) once a day for a total study duration of 48 weeks.

Rationale: The paper describes two different treatment arms: one switching to DTG + bDRV and one continuing 2NRTI + bDRV, so not all individuals received the same ART.

Answer: No
"""

"""
Question: 4305

Evidence: Exclusion criteria were documented major darunavir or INSTI resistance.

Rationale: The paper states that individuals with documented INSTI resistance were excluded, and since dolutegravir was part of the intervention being studied, participants were INSTI-naive at baseline.

Answer: Yes
"""

"""
Question: 4403

Evidence: 20.9% in the 2DR group and 11.0% in the 3DR group had a history of ≥2 NRTI and ≥2 PI changes, respectively.

Rationale: The paper reports that some participants had a history of multiple ART regimen changes, but does not provide specific numbers of individuals who received more than one ART regimen.

Answer: NA
"""

"""
Question: 4404

Evidence: 20.9% in the 2DR group and 11.0% in the 3DR group had a history of ≥2 NRTI and ≥2 PI changes, respectively.

Rationale: The paper reports that some participants had ahistory of multiple ART regimen changes, but does not provide specific numbers of individuals who received more than two ART regimens.

Answer: NA
"""

"""
Question: 4405

Evidence: 20.9% in the 2DR group and 11.0% in the 3DR group had a history of ≥2 NRTI and ≥2 PI changes, respectively.

Rationale: The paper indicates that participants had varying numbers of previous ART regimen changes, with some having multiple changes, so not all individuals received the same number of ART regimens.

Answer: No
"""

"""
Question: 4406

Evidence: 20.9% in the 2DR group and 11.0% in the 3DR group had a history of ≥2 NRTI and ≥2 PI changes, respectively.

Rationale: The paper reports that some participants had multiple ART regimen changes, indicating that not all individuals received only one ART regimen.

Answer: No
"""

"""
Question: 4501

Evidence: In total, 263 subjects were randomized and treated (2DR n = 131, 3DR n = 132). Subjects were randomized 1:1 using a sequence generated with nQuery Advisor 7.0 (Statsols, Cork, Ireland) to either receive oral DTG 50 mg once daily in combination with DRV 800 mg once daily and ritonavir 100 mg daily (2DR) or continue their regimen consisting of 2 NRTIs in combination with ritonavir-boosted DRV (3DR) once a day for a total study duration of 48 weeks.

Rationale: The paper states that 131 subjects were randomized to the 2DR group that received dolutegravir (DTG).

Answer: 131
"""

"""
Question: 4502

Evidence: In total, 263 subjects were randomized and treated (2DR n = 131, 3DR n = 132). Subjects were randomized 1:1 using a sequence generated with nQuery Advisor 7.0 (Statsols, Cork, Ireland) to either receive oral DTG 50 mg once daily in combination with DRV 800 mg once daily and ritonavir 100 mg daily (2DR) or continue their regimen consisting of 2 NRTIs in combination with ritonavir-boosted DRV (3DR) once a day for a total study duration of 48 weeks.

Rationale: The paper states that all 263 subjects received darunavir (DRV), either in the 2DR group (n=131) or the 3DR group (n=132).

Answer: 263
"""

"""
Question: 5101

Evidence: Relevant rates of NRTI, non-NRTI, and major PI resistance--associated mutations (RAMs) were observed in 9.9% vs 9.1%, 15.3% vs 13.6%, and 3.8% vs 3.0% of the 2DR and 3DR groups, respectively.

Rationale: The paper reports prevalence rates of drug resistance mutations by drug class but does not provide the total number of individuals found to have one or more drug resistance mutation across all classes.

Answer: NA
"""

"""
Question: 5102

Evidence: No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: The paper specifically states that no treatment-emergent resistance developed during the study, including no INSTI-resistance mutations.

Answer: 0
"""

"""
Question: 5103

Evidence: No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: The paper specifically states that no treatment-emergent resistance developed during the study, including no TDF-resistance mutations.

Answer: 0
"""

"""
Question: 5104

Evidence: No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: The paper explicitly states that no treatment-emergent resistance mutations developed during the study for any drug class, including INSTI-resistance mutations.

Answer: None
"""

"""
Question: 6101

Evidence: No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: The paper does not mention any phenotypic susceptibility testing being performed.

Answer: NA
"""

"""
Question: 6102

Evidence: No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: The paper does not report any IC values like IC50 or IC90, as it focuses on clinical outcomes rather than laboratory susceptibility testing.

Answer: No
"""

"""
Question: 6103

Evidence: No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: The paper does not report any IC50 fold change values, as it does not include phenotypic susceptibility testing data.

Answer: No
"""

"""
Question: 6104

Evidence: No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: The paper does not mention any phenotypic susceptibility assays being used.

Answer: NA
"""

"""
Question: 6105

Evidence: No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: The paper does not report any data about replication capacity.

Answer: No
"""

"""
Question: 6106

Evidence: No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: The paper does not mention any drugs being tested in phenotypic susceptibility assays.

Answer: NA
"""

"""
Question: 7101

Evidence: No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: The paper describes a clinical trial with human subjects and does not mention any site-directed mutations being created or studied.

Answer: No
"""

"""
Question: 7102

Evidence: No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: The paper does not mention any in vitro passage experiments being conducted; it focuses solely on clinical outcomes from the randomized trial.

Answer: No
"""